ConductScience.org, home

Paper41345965

Evaluation of the safety and immunogenicity of a peptide vaccine against canine leishmaniosis: a double-blind, multicenter, controlled clinical trial in dogs.

Hurtado-Morillas C and 6 others. Vet Q, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Evaluation of the safety and immunogenicity of a peptide vaccine against canine leishmaniosis: a double-blind, multicenter, controlled clinical trial in dogs. Papers, record 41345965. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345965

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of the safety and immunogenicity of a peptide vaccine against canine leishmaniosis: a double-blind, multicenter, controlled clinical trial in dogs.
PubMed
Journal
Vet Q
PubMed
Year
2025
PubMed
Publication types
Journal Article, Multicenter Study, Clinical Trial, Veterinary
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-12-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hurtado-Morillas CClara
2Mas AAlicia
3Orden JAJosé A
4de Urbina-Fuentes LLaura
5Blanco MMM Mar
6Domínguez-Bernal GGustavo
7Martínez-Rodrigo AAbel

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dog DiseasesMajor topic
Leishmania infantumMajor topic
Leishmaniasis, VisceralMajor topic
Leishmaniasis VaccinesMajor topic
Animals
Dogs
Double-Blind Method
Female
Male
Vaccines, Subunit
Immunogenicity, Vaccine
Antibodies, Protozoan
Protein Subunit Vaccines

Source PubMed

Download CSV of topics

References64

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137631952Intramuscular Immunization with a Liposomal Multi-Epitope Chimeric Protein Induces Strong Cellular Immune Responses against Visceral Leishmaniasis.Vaccines (Basel)2023https://conductscience.org/library/papers/37631952PubMed
237251529Advances in Computational and Bioinformatics Tools and Databases for Designing and Developing a Multi-Epitope-Based Peptide Vaccine.Int J Pept Res Ther2023https://conductscience.org/library/papers/37251529PubMed
334089789Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice.Microb Pathog2021https://conductscience.org/library/papers/34089789PubMed
429027520Further evidence associating IgG1, but not IgG2, with susceptibility to canine visceral leishmaniasis caused by Leishmania (L.) infantum chagasi-infection.Parasite2017https://conductscience.org/library/papers/29027520PubMed
533139752Infection of dogs by Leishmania infantum elicits a general response of IgG subclasses.Sci Rep2020https://conductscience.org/library/papers/33139752PubMed
637569710A Tailored Approach to Leishmaniases Vaccination: Comparative Evaluation of the Efficacy and Cross-Protection Capacity of DNA vs. Peptide-Based Vaccines in a Murine Model.Int J Mol Sci2023https://conductscience.org/library/papers/37569710PubMed
723562649Asymptomatic dogs are highly competent to transmit Leishmania (Leishmania) infantum chagasi to the natural vector.Vet Parasitol2013https://conductscience.org/library/papers/23562649PubMed
832317026Latest trends in Leishmania infantum infection in dogs in Spain, Part I: mapped seroprevalence and sand fly distributions.Parasit Vectors2020https://conductscience.org/library/papers/32317026PubMed
937562277TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease.Immunobiology2023https://conductscience.org/library/papers/37562277PubMed
1029525281A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis.Vaccine2018https://conductscience.org/library/papers/29525281PubMed
1131300103Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection.Comp Immunol Microbiol Infect Dis2019https://conductscience.org/library/papers/31300103PubMed
1231214607Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis.Front Vet Sci2019https://conductscience.org/library/papers/31214607PubMed
1328114333
Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.
PLoS Negl Trop Dis2017https://conductscience.org/library/papers/28114333PubMed
1439355141Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review.Front Vet Sci2024https://conductscience.org/library/papers/39355141PubMed
1519666153The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection.Vaccine2009https://conductscience.org/library/papers/19666153PubMed
1631303211Canine visceral leishmaniasis biomarkers and their employment in vaccines.Vet Parasitol2019https://conductscience.org/library/papers/31303211PubMed
1728242002Canine peripheral blood CD4+CD8+ double-positive Tcell subpopulations exhibit distinct Tcell phenotypes and effector functions.Vet Immunol Immunopathol2017https://conductscience.org/library/papers/28242002PubMed
1822789871Canine CD4+CD8+ double positive T cells in peripheral blood have features of activated T cells.Vet Immunol Immunopathol2012https://conductscience.org/library/papers/22789871PubMed
1929547503Parasite Specific Antibody Levels, Interferon-γ and TLR2 and TLR4 Transcripts in Blood from Dogs with Different Clinical Stages of Leishmaniosis.Vet Sci2018https://conductscience.org/library/papers/29547503PubMed
209431920Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis.J Clin Microbiol1998https://conductscience.org/library/papers/9431920PubMed

See all 64 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41345965

GET https://conductscience.org/api/papers/v1/41345965/references?page=2